FOLH1 and nonpapillary renal cell carcinoma: Among non-ccRCC, patients with FOLH1-high and -low tumors had similar cabozantinib TOT (8.1 versus 1.4 months, HR 1.26, 95% CI 0.31–5.1, p = 0.748) and nivolumab +/− ipilimumab TOT (3.0 versus 4.3 months, HR 1.21, 95% CI 0.43–3.38, p = 0.734).